Obesity, Low-Carb Diets and the Atkins Revolution: Healthy Profits from Big Issues in Food and Drinks is among several in-depth reports on consumer marketing trends now offered through FDC Reports. The report contains primary research from an industry opinion survey of over 4,000 senior executives in the global food and drink industry. The 1Datamonitor report is available through FDC Reports by contacting Denise Peterson at 2d.peterson@elsevier.com or 301-664-7143. FDC Reports is offering a number of Datamonitor reports spanning the prescription and OTC drug industries as well as focused consumer marketing studies...
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
The UK drug regulator acknowledges that technology will “move on” and, as such, has designed its decentralized manufacturing regulation to be as “enduring” as possible. Experts from the MHRA explain what products are covered by the new framework and how it has been future-proofed.
The European Medicines Agency expects the International Council for Harmonization’s new guideline will help address the critical lack of data on the use of medicinal products in pregnant and breastfeeding populations.
A differentiated profit-sharing model to accelerate the use of AI in drug development using clinical and patient data is being proposed in South Korea, but the idea faces multiple practical challenges
